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Abstract: Hepatitis E virus (HEV) is an underdiagnosed pathogen with approximately 20 million
infections each year and currently the most common cause of acute viral hepatitis. HEV was long
considered to be confined to developing countries but there is increasing evidence that it is also a
medical problem in the Western world. HEV that infects humans belongs to the Orthohepevirus A
species of the Hepeviridae family. Novel HEV-like viruses have been observed in a variety of animals
and some have been shown to be able to cross the species barrier, causing infection in humans.
Several cell culture models for HEV have been established in the past years, but their efficiency is
usually relatively low. With the circulation of this virus and related viruses in a variety of species,
several different animal models have been developed. In this review, we give an overview of these
animal models, indicate their main characteristics, and highlight how they may contribute to our
understanding of the basic aspects of the viral life cycle and cross-species infection, the study of
pathogenesis, and the evaluation of novel preventative and therapeutic strategies.
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1. Introduction
Hepatitis E virus (HEV) was discovered in the early 1980s as a causative agent of non-A, non-B
hepatitis (NANB), and is currently one of the major causes of acute viral hepatitis worldwide [1]. It is
a quasi-enveloped, single-stranded RNA virus with a positive-sense genome that is approximately
7.2 kb in size [2]. The viral genome comprises three open reading frames (ORF 1–3), which are
flanked by 5′ and 3′ untranslated regions (UTR) [2]. At the end of the 5′ UTR a 7-methylguanylate
(m7G) cap is present, which drives cap-dependent genome translation. The 3′ UTR, which is about
65 nucleotide long, possesses a poly-adenylated tail [2]. ORF1 encodes a 1693-amino-acid-long
nonstructural polyprotein, which is comprised of functional domains that are essential for viral genome
replication [3,4]. There is still controversy and uncertainty regarding whether this polyprotein is
proteolytically processed following translation, as is the case for other positive-strand RNA viruses [5].
ORF2 and ORF3, which are overlapping, are encoded from a bicistronic subgenomic RNA [6]. ORF2
encodes the viral capsid protein, which encapsulates the viral genome. The capsid protein possesses
three domains: the S (shell), M (middle), and P (protruding) domains. The M and P domains are
believed to play vital roles during virus entry [7]. More recently, it was shown that ORF2 also encodes
a secreted form (ORF2S), for which the biological role needs to be further elucidated. In cell culture,
ORF2S had the ability to reduce antibody-mediated translation [8,9]. ORF3 encodes a phosphoprotein
that plays an important role during viral particle morphogenesis [10].
HEV is classified into the family of the Hepeviridae. There are two recognized genera under
this family, namely the Orthohepevirus, which comprises all mammalian and avian HEV isolates,
and the Piscihepevirus, which comprises the closely related cutthroat trout virus [11,12]. The genus
Viruses 2019, 11, 564; doi:10.3390/v11060564 www.mdpi.com/journal/viruses
Viruses 2019, 11, 564 2 of 20
Orthohepevirus encompasses four species, Orthohepeviruses A to D. Classification into species is based
on host range and sequence identity [6].
Orthohepevirus A consists of 8 major genotypes. Genotypes 1 and 2 can solely infect humans.
Isolates from these genotypes are primarily transmitted via fecal-oral route, thereby causing waterborne
hepatitis outbreaks in regions of poor sanitation in Asia, Africa, and Central America, with an estimated
amount of 20 million infected people each year [13]. Infections mostly result in a self-limiting acute
icteric hepatitis. However, in certain patient groups, it is associated with progressive liver disease,
leading to fulminant hepatitis and death. Mortality rates are generally low but increase in infants
under 2 years and reach 25% in pregnant women [14,15].
Genotype 3 and 4 HEV are responsible for autochthonous infections in developed countries.
Genotype 3 has been isolated from pigs, wild boar, rabbits, deer, mongooses, and rats. However,
rats are not the main hosts for genotype 3 HEV, but rather for specific rat HEV belonging to the
Orthohepevirus B species, as stated below. Genotype 3 HEV has been isolated from rats in the United
States, but could not be retrieved from Eastern European rats, so further confirmation is needed [16,17].
Genotype 4 HEV has been reported to be predominantly found in domestic and wild swine, as well as
in sheep [5]. Infections with these genotypes are mainly zoonotic, via consumption of undercooked
contaminated animal products [6]. However, other transmission routes have also been described.
HEV RNA was previously detected in leafy green vegetables and on-field grown strawberries, which
probably originated from use of contaminated irrigation or surface water [18,19]. Coastal waters can
also become contaminated with HEV via polluted rivers or sewage water, leading to the presence of
the virus in shellfish [20]. Shellfish consumption is a risk factor for acquiring HEV, as these are mostly
eaten raw or only slightly cooked. Shellfish have been implicated as a viral source in several European
case reports, as well as for an HEV outbreak on a cruise ship [21–24]. Moreover, studies in the United
Kingdom have shown a coastal clustering of HEV, as an increase in patients is observed within two
kilometers of the sea [22,25]. The exact reason remains to be clarified but could be related to increased
consumption of shellfish and environmental factors, such as flooding in the area leading to increased
exposure of waterborne pollutants [25].
Direct contact with infected animals may also lead to HEV, as higher seroprevalence rates occur
in swine workers, veterinarians, and pork butchers. Additionally, blood-borne transmission has
been described [26]. Infections with genotype 3 and 4 mostly resolve spontaneously, but chronic
HEV may occur in immunocompromised persons, such as organ transplant recipients, persons with
hematological malignancies, HIV-infected individuals, and rheumatological patients [27,28].
HEV of Genotype 5 and 6 have only been described in wild boar, whereas isolates from camels are
classified into genotype 7 and 8 [11]. Interestingly, camel HEV (genotype 7) was isolated from a patient
in the Middle East who had regularly been consuming camel meat and milk, and may therefore also
pose a risk for zoonotic infection [4].
Beside the abovementioned animals, anti-HEV antibodies have also been detected in dogs, cats,
cattle, goats, and horses, without knowing the source of seropositivity [29]. For horses in particular,
independent studies in China, Egypt, and Spain demonstrated a seroprevalence ranging from 0.8% to
16.6% [30–32]. Phylogenetic analyses showed a close relationship with previously described human
and swine HEV. Further research is needed to verify if horses are true reservoirs or rather spillover
hosts [30].
Next to HEV, isolates belonging to the Orthohepevirus A species, a variety of HEV-like viruses, have
been identified in other animal species. Isolates from chickens belong to Orthohepevirus B, whereas
isolates from rats, greater bandicoots, Asian musk shrews, ferrets, and mink belong to Orthohepevirus C.
Isolates from bats belong to Orthohepevirus D [33]. Recently, a 56-year-old Chinese liver transplant
patient was reported to have been infected by rat HEV and the infection manifested as a persistent
hepatitis, highlighting the potential of rat HEV to cause zoonosis [34].
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Although self-limiting in immunocompetent individuals, HEV still poses a global health burden
with a potential threat to food safety, especially given the ever expanding range of HEV and HEV-like
agents. Efforts must, thus, be undertaken to better understand the nature of this pathogen [35].
Just like other hepatitis viruses, HEV is tremendously difficult to propagate in cell culture.
However, recent breakthroughs in this field have been made and have led to a lot of progress in
understanding the molecular biology of HEV [36]. Several HEV isolates, such as the genotype 3
JE03-1760F strain, isolated from a Japanese patient with acute hepatitis E, and the genotype 4 HE-JF5/15F
strain, isolated from a fulminant hepatitis patient with high viral load, have been used in various
studies to decipher the molecular biology of HEV [6,37,38]. These two strains have been reported to
replicate efficiently and generate reasonable viral titers when cultured in PLC/PRF/5 and A549, which
are human hepatocellular carcinoma and human lung cancer cell lines, respectively [38,39]. More
recently, the genotype 3 Kernow C1 (passage 6) strain, derived from a chronically HIV-HEV-infected
patient and containing an in-frame insertion of 58 amino acids from the ribosomal protein S17, was
shown to robustly replicate in Huh7 and HepG2/C3a liver cell lines, making it vital for cell culture
studies. Furthermore, the insertion also widened host tropism [40,41].
Although cell culture systems have been instrumental in understanding some basic aspects
of the molecular biology of HEV and the evaluation of novel antivirals, they are not suitable to
help the scientific community in understanding the viral pathogenesis, including differences of HEV
genotypes [5].
To dissect the in vivo characteristics of HEV infection and understand the viral pathogenesis,
animal models are indispensable tools [42]. The circulation of HEV in a variety of animal species has
led to the usage of several naturally occurring animal models. The ultimate animal model for HEV is
fully immunocompetent, susceptible to distinct HEV strains that are able to cause infection in humans,
and mimics the associated clinical disease. Ideally, this model is cheap, easy to handle and propagate,
can be genetically manipulated, and comes with no or only limited ethical constraints. In this review
we provide an overview of the currently available animal models for HEV. There is no model that
fulfills all of the above-mentioned criteria, but each of the existing models have been requisite to a
better understanding of this virus.
2. Non-Human Primate Model
2.1. Experimental Infection of Non-Human Primates
Non-human primates (NHP) are not a natural host for HEV, however they have been shown
to be susceptible to experimental infection of genotypes 1, 2, 3, and 4 [43–46]. The first experiments
using this model were performed on cynomolgus macaques. During the discovery of HEV as
enterically transmitted non-A, non-B hepatitis in 1983, a human volunteer ingested stool samples
derived from Afghan patients during a hepatitis outbreak. He developed symptoms of acute viral
hepatitis whereupon his stool, containing virus-like particles (VLPs), was intravenously inoculated
into cynomolgus macaques. Subsequently, it was confirmed that the agent was able to cause
histopathological and enzymatical hepatitis in the macaques. Moreover, VLPs were excreted in the
feces and a VLP-specific antibody response was observed [47].
After initial infection of cynomolgus macaques, also other NHP were used to study HEV. Purcell
et al. performed a study to compare HEV infection in chimpanzees, cynomolgus, and rhesus macaques.
Chimpanzees seemed to be slightly more susceptible to infection with HEV genotype 1 compared
with cynomolgus and rhesus macaques, but it appeared that the same strain was more virulent in the
macaques, shown by the elevation of liver enzymes. Moreover, rhesus monkeys were used to examine
the difference in virulence between HEV genotypes. Genotype 3 HEV was significantly less virulent
than human genotype 1 and 2 [44].
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Pig-tailed macaques, vervets, owl monkeys, squirrel monkeys, and patas monkeys can all
readily be infected with HEV, whereas studies in tamarins yielded mixed results as not all developed
infection [48–50].
Infection of these animals is mostly performed intravenously. Oral inoculation has also been
performed but failed in most trials. It was reported that oral inoculation of cynomolgus macaques
required at least a 10,000-fold higher dose than intravenous inoculation in order to establish an
active HEV infection [46]. The course of infection in NHP is similar to humans but with levels of
viral shedding, liver enzyme elevation, and histopathologic changes in the liver that differ between
the species.
2.2. NHP as Animal Model for HEV
Because of the abovementioned studies, it is accepted that chimpanzees, cynomolgus, and rhesus
macaques are the most suitable models for HEV [51]. Chimpanzees and rhesus monkeys are susceptible
to human HEV of genotypes 1 to 4. Cross-species infection studies showed that other zoonotic strains
could also infect NHP. Chimpanzees and rhesus monkeys are susceptible to animal HEV of genotypes
3 and 4 [52]. Cynomolgus macaques could also be infected with a Chinese rabbit isolate of HEV and
resulted in a typical HEV course with elevated liver enzymes, viremia, virus shedding in feces, and
seroconversion [53]. Cynomolgus macaques were shown to be susceptible to an infectious gt 5 strain,
generated by reverse genetics. This suggests that gt 5 may not only be confined to wild boar but has
the ability to cause zoonosis [54]. Moreover, cynomolgus macaques could be infected with a gt 8 strain,
isolated from Bactrian camels in China. Viremia, urinary, and fecal shedding of virus, elevation of liver
enzymes, and seroconversion to anti-HEV IgM and IgG were all observed, as well as extra-hepatic
replication. In one of the two tested animals, the virus persisted until week 25 after infection, which
may present a chronic course in this animal. Further follow-up could not be achieved due to the
unexpected death of the animal [55]. Attempts to infect cynomolgus and rhesus macaques with avian,
rat, and ferret HEV have failed [56–58].
Next to testing the infectivity of different HEV genotypes, NHP models were also used to test
infectious cDNA clones. Using RNA transcripts from variants of cDNA clones, it was confirmed that
the 5′ cap is essential for infectivity of the virus [59]. Generation of such full-length functional clones
provides opportunities to study the molecular biology of HEV in primates.
In an attempt to study HEV pathogenesis during pregnancy, 4 non-pregnant and 6 pregnant
rhesus monkeys in the three different trimesters of pregnancy were inoculated intravenously with
genotype 1 HEV. Unfortunately, the severe clinical course of fulminant hepatitis typically observed in
pregnant women infected with HEV was not observed in the pregnant rhesus monkeys. In addition,
the infection did not transmit from infected mothers to their offspring [60].
Cynomolgus macaques were also used to study chronic HEV and were persistently infected with a
gt 3 HEV strain when being treated with tacrolimus, a potent calcineurin inhibitor immunosuppressant.
Thereby, this situation mimics immunocompromised patients. Chronic infection in these animals
was observed with a mild increase of liver enzymes serum levels, persistent RNA viremia, viral fecal
shedding, and severe hepatic lesions [61].
Rhesus and cynomolgus macaques were also proven to be excellent models to evaluate the efficacy
of potential HEV vaccines. Based on data observed in these animals, two HEV vaccine candidates
containing recombinant HEV capsid antigen were applied to phase 2 and phase 3 trials in humans [43].
The first vaccine, HEV 239 (Hecolin®, China), contains a peptide encompassing 368–606 aa of ORF2
derived from a genotype 1 HEV Chinese strain expressed in Escherichia coli [62]. Rhesus macaques were
vaccinated, after which they developed anti-HEV antibodies and were protected against challenge with
homologous genotype 1 or heterologous genotype 4 HEV [63,64]. After extensive study of this vaccine
in clinical trials with 100% protection for genotype 1 and 4 HEV, the vaccine was licensed in China in
2012, and is therefore the first commercial HEV vaccine [65,66]. Formal proof of its activity against
genotype 2 and 3 HEV is, however, still lacking. Another recombinant HEV vaccine, consisting of a
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56 kDa protein derived from capsid antigen ofthe gt 1 Pakistani Sar55 strain was expressed in insect
cells from a baculovirus vector [62,67,68]. Several consecutive studies using this vaccine in cynomolgus
and rhesus macaques showed the immunogenicity and efficacy in preventing HEV infection upon
challenge with genotypes 1–3 HEV [67,68]. Subsequently, the vaccine was tested in human trials and
showed 95% protection against genotype 1 HEV in military troops in Nepal [69].
2.3. Limitations of NHP Models
Although many studies have been carried out using NHP, they come with some disadvantages.
As stated above, NHP are not a natural host of HEV and the observed clinical presentations of disease
are sometimes limited. Moreover, chronic HEV as observed in immunocompromised patients infected
with genotype 3 HEV has not yet been remodeled in primates. The use of these animals in future
research is also limited due to ethical concerns, and invasive biomedical research in chimpanzees
among other great apes is now severely restricted. Additionally, these animals may be difficult in
operation with limited procedures, and come with a high cost [51].
3. Pig Model
3.1. Swine HEV and Course of Infection in Swine
Swine HEV was first discovered and characterized in 1997 in the United States and was, therefore,
the first known animal strain of HEV [70]. It was shown that the majority of pigs older than 3 months
were positive for anti-HEV IgG, indicating a high seroprevalence in commercial pig herds. Additionally,
a prospective study was set up in these commercial herds to identify the HEV-related agent causing
the seropositivity. According to previous sero-epidemiological data observed in pig herds, 18 of the
21 pregnant sows in this study tested positive for anti-HEV. Of those pregnant sows, 20 piglets were
monitored for over 5 months to assess HEV infectivity. By 21 weeks of age, 16 of 20 studied piglets had
seroconverted. Further genetical characterization revealed that swine HEV was closely related but
distinct from human HEV of genotype 3 and 4, with a nucleotide sequence similarity of 79–80% and
90–92% on amino acid levels, respectively [70].
Since this initial discovery of swine HEV, it has become clear that swine represent a natural
reservoir for HEV of genotype 3 and 4. Pigs become infected with the virus due to direct contact with
an infected animal or through ingestion of feces-contaminated feed or water [71]. Experimentally,
pigs are infected with swine HEV mostly by intravenous inoculation. Experimental infection via oral
route has been difficult as detection of viremia, fecal shedding, or seroconversion to anti-HEV IgG
could not always be observed [51,72]. After infection, pigs have transient viremia of about 1 to 2 weeks
and shed the virus in large amounts in feces for 3 to 7 weeks. HEV infection in both naturally and
experimentally infected pigs does not result in observable clinical disease or elevation in liver enzymes,
however, several microscopic histopathological lesions can be observed, such as mild to moderate
multifocal and periportal lymphoplasmacytic hepatitis and mild focal hepatocellular necrosis [71,73].
3.2. Pigs as an Animal Model for HEV
As natural reservoir for HEV of genotype 3 and 4, pigs serve as an important homologous animal
model system. Specific-pathogen-free pigs can be readily infected with HEV of genotype 3 and 4
isolated from humans [74–77]. Moreover, HEV strains from other animals have been shown to cross
the species barrier and cause infection in pigs. Inoculation with rabbit HEV, which is also a distant
member of genotype 3, led to viremia and fecal virus shedding [78].
Shortly after the discovery of swine HEV and the identification of pigs as a homologous animal
model, this model was used to study HEV replication. This resulted in the demonstration that the
virus not only replicates in the liver, but also in extrahepatic sites, such as the small intestine, colon,
and lymph nodes [79].
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The pig model has also been used to assess the infectivity of capped full-length HEV RNA
transcripts from infectious clones. These swine HEV infectious cDNA clones give an opportunity to
study the basic biology of HEV and potential mechanisms of zoonotic transmission, as swine/human
chimeric viruses can be constructed [80]. Thanks to this model it was also revealed that the initiation
site of ORF3 is essential for viral infectivity in vivo and that the hypervariable region of ORF1 is
unnecessary for infection and replication [81–83].
Vaccine studies have also been performed in pigs. Research showed that prior genotype 3 swine
HEV infection prevented pigs from developing viremia and fecal virus shedding upon challenge with
homologous swine HEV and heterologous human HEV strains. This finding is important as it may
illustrate that a vaccine derived from one HEV genotype is sufficient to elicit protective immunity
against other HEV genotypes [84]. Moreover, truncated recombinant capsid antigens derived from
pig, rat, and chicken HEV strains could induce strong anti-HEV IgG responses in pigs and partially
cross-protect against genotype 3 HEV [85].
More recently, a pig model mimicking chronic HEV was established by orally administrating a
combination of 3 classical immunosuppressive drugs. Viral shedding in these pigs lasted 5–14 weeks
longer than in immunocompetent pigs. Moreover, the pigs mimicked the immune response status of
chronically infected human solid-organ transplant recipients. In the future, this model can be used to
elucidate the mechanism of HEV pathogenesis and immune responses during chronic HEV infection,
and to develop or evaluate antiviral treatments [86].
3.3. Limitations of the Pig Model
Although pigs have shown to be a useful model for HEV genotype 3 and genotype 4, they are
not susceptible to genotype 1 and 2, which account for most of the clinical cases. Additionally, not all
aspects of clinical disease are represented in pigs infected with genotype 3 and 4. Finally, pigs are also
expensive, and due to their posture, not so easy to handle.
4. Rabbit Model
4.1. Rabbit HEV and Course of Infection in Rabbits
In 2009, the first rabbit HEV strain was isolated from a farm in China [87]. Since then, different
rabbit strains across the globe have been found, suggesting that rabbits are a natural host for HEV [88–92].
After inoculation with different rabbit HEV strains, a typical course of acute HEV infection can be
observed—virus is shed in the feces, liver enzymes are elevated, histopathological changes in the liver
can be observed, HEV-specific antibodies appear, and the animals become viremic [93].
Interestingly, Han et al. showed that rabbits inoculated with the homologous CHN-BJ-rb14 HEV
strain, had prolonged viremia and fecal shedding, indicating a chronic HEV infection [94]. Fecal
shedding of the virus lasted for 9 months, and thereby exceeds the arbitrary 6-month definition of
chronic infection [95]. In addition, liver histopathology showed chronic inflammatory cell infiltration
and portal fibrosis [94]. In a subsequent study, a link between the viral dose and the development of
chronic infection was suggested [96].
Rabbits experimentally infected with rabbit HEV also presented with extrahepatic replication in
different tissues, such as the brain, heart, lungs, stomach, intestine, kidney, and placenta. Likewise,
the chronically infected rabbits from the abovementioned study also presented with extrahepatic
replication of HEV in the kidneys, suggesting that the observed lesions in this organ may have been
induced by replication of the virus [96].
4.2. Rabbit as Animal Model for HEV
Rabbits are an attractive naturally occurring animal model for HEV research because of the
viral genome sequence similarity between rabbit HEV and genotype 3 HEV that infects humans [97].
In fact, rabbit HEV was detected in 5 out of 919 HEV infected human subjects in France between
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2015–2016 [98], suggesting zoonotic transmission. The strain isolated from these patients had an
additional 93 nucleotides in the X-domain of ORF1, similar to viruses isolated from farmed and wild
rabbits [91,98].
Rabbits can be successfully infected with human genotype 4 HEV, indicated by viral shedding in
stool, elevation of liver enzymes, and histopathological changes in the liver [93,99].
Interestingly, when swine genotype 4 HEV, which also infects humans, was inoculated
intraperitoneally into rabbits, it induced a productive infection that was evidenced by viral shedding
in stool, viremia, and presence of HEV anti-sense RNA in the spleen, indicating extra-hepatic HEV
replication [100]. Recently, Schlosser et al. succeeded in infecting rabbits with a wild-boar derived
genotype 3 HEV. The animals shed virus in the feces and seroconverted four to five weeks post
inoculation. Moreover, viral RNA was demonstrated in liver and gall bladder [101]. This data shows
that rabbits could become handy in studying cross-species infection.
Another intriguing feature of HEV infection is the high morbidity and mortality among pregnant
women [102]. Although the reason behind this is still unclear, immunological and hormonal changes
during pregnancy may play a role [103]. In this line, Ahn et al. inoculated pregnant rabbits with rabbit
HEV of strain KOR-Rb-1. The group observed that compared to the controls, the infected rabbits
expressed significantly higher levels of aspartate transaminase, TNF-α, and IFN-γ, suggesting that
these could possibly influence the outcome of HEV infection during pregnancy [104]. Elsewhere,
Xia et al. reported that three out of the six experimentally infected pregnant rabbits died, while two of
the remaining three miscarried [97]. Liver histopathology showed gross necrosis and infiltration of
inflammatory cells. The presence of positive and negative sense RNA in the placental cells indicated
vertical transmission [97]. Interestingly, Knegendorf et al. observed that HEV genotype 1 and 3
efficiently replicate and produce infectious viral particles in human-derived placental cells (JEG-3) [105].
Clearly, rabbit models open several doors to help us understand HEV pathogenesis during pregnancy.
HEV has been associated with some neurological extrahepatic manifestations. Tian et al. have
used rabbits to investigate how the virus invades the nervous system. HEV RNA, as well as HEV ORF2
protein, could be detected in both brain and spinal cord. The CNS infections were also associated
with pathological changes, including perivascular cuffs of lymphocytes and microglial nodules. These
findings suggest that rabbits could also be a potential model to study HEV-associated neurological
disorders [106].
Rabbits have also been used in HEV vaccine studies [99,107]. Cheng et al. administered 0, 10,
and 20 µg of an HEV vaccine candidate p 179 to rabbits and then challenged them with a genotype 4
isolate (strain H4-NJ703). All the rabbits that received a 20 µg dose were protected from infection [99].
In another study, the HEV 239 vaccine was evaluated in rabbits for its efficacy at different doses.
Results showed that administering two 10 µg doses of HEV 239 induced the best immune response in
rabbits in comparison with two 20 µg doses or a single 30 µg dose [107]. In the work by Schlosser et al.,
rabbits immunized with recombinant rat HEV capsid proteins were protected from HEV genotype
3 infection [101]. From these three studies we can appreciate that rabbits present a good model for
evaluating prophylactic vaccines and also possibly antiviral drugs. Although promising, more work
needs to be done.
4.3. Limitations of the Rabbit Model
Rabbits are small animal models and have proven to be useful for cross-species infection,
pathogenesis, pregnancy, and vaccine studies. However, it would be of great interest to establish
such a kind of animal mimicking natural HEV-3 infection to help understand disease, and therefore
provide novel insights into HEV replication. In regard to this, previous studies where rabbits were
infected with human HEV of genotype 3 showed seroconversion but failed to show viral replication
and shedding in feces [99,108]. In addition, rabbits are also resistant to human genotype 1 HEV [99].
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5. Rat Model
5.1. Rat HEV and Course of Infection in Rats
Rat HEV was initially detected in Rattus norvegicus in Germany [109]. It is categorized under the
species Orthohepevirus C and divided into three genetic groups [11,110]. When compared with human
HEV, the nucleotide sequence similarity is approximately 60% [6]. Phylogenetic analysis indicates
that rat HEV is much more related to ferret HEV [111]. Rattus norvegicus and Rattus rattus are among
several rat species that are natural hosts of rat HEV. Over the years, rat HEV has been isolated from rats
in Asia, the United States, and some countries in Europe [5]. In both wild and laboratory rats, rat HEV
infection is not robust [57]. Purcell et al. showed that experimental infection of Sprague-Dawley rats
was inconsistent and the magnitude of the infection was not sapid [57]. Although previously thought
not to infect humans [57], it has recently been reported that rat HEV caused persistent hepatitis in a
liver transplant patient in China [34]. This clearly shows the potential of zoonotic transmission.
5.2. Rat as Animal Model for HEV and the Associated Limitations
Establishing persistent HEV infection in laboratory rats had been challenging until recently when
rat HEV, strain LA-B350, was reported to productively infect athymic nude rats [112]. In this work,
Debing et al. observed that upon intravenous inoculation of LA-B350, viral RNA could be detected in
stool as early as 4 days post-inoculation in all the infected animals. In fact, viral titers in serum reached
about 4 × 106 copies/mL [112]. Experimental infection of Wistar rats with mammalian HEV genotypes
1, 2, 3, and 4 has not been very successful. Maneerat et al. could demonstrate the presence of HEV RNA
in stool of rats inoculated with a stool suspension of human HEV strain of undisclosed genotype [113].
In contrast, in the study of Schlosser et al., Wistar rats seemed resistant to intravenous inoculation
of HEV-1 derived from a cynomolgus monkey, of HEV-3 derived from a domestic pig, and of HEV-4
derived from wild boar [101]. This shows that athymic nude rats might be the best surrogate model for
studying HEV pathogenesis. However, lack of a functional immune system in these rats will prevent
us from analyzing the impact the adaptive immune system plays in active pathological hepatitis [114].
6. Mouse Model
6.1. Mouse as Animal Model for HEV Infection
Most human pathogens do not naturally infect mice due to divergent host adaptation that has
occurred over the years of evolution. To utilize mice as a model for studying human-specific pathogens,
mice are genetically engineered to express specific human factors that render them susceptible to human
pathogens [115,116]. Like other hepatitis viruses, human HEV does not naturally infect mice [101].
However, a few studies have recently shown that experimental infection of human liver chimeric
mice with HEV genotype 1 and genotype 3 resulted in robust infection [117–119]. The hepatocytes
of these mice are replaced by functional primary human hepatocytes, which can be achieved after
introduction of severe liver disease [120]. First of all, this can be accomplished in mice carrying
the mouse urokinase-type plasminogen activator (uPA) gene as a transgene under the control of
the albumin enhancer/promotor (Alb-uPA). Overexpression of the uPA-gene in the liver results in
severe liver injury allowing repopulation by transplanted human hepatocytes. To prevent rejection of
the xenogeneic transplanted human hepatocytes, the uPA-mice first need to be backcrossed with an
immune deficient mouse, such as the severe combined immunodeficient (SCID) mouse [121,122]. Using
homozogous uPA-SCID mice, human hepatocytes integrate and repopulate up to 90% of mouse liver
parenchyma [123]. A second option is to use mice carrying the fumarylacetoacetate hydrolase gene
knockout (FAH-/-). Knockout of this essential enzyme taking part in the tyrosine catabolic pathway
causes accumulation of hepatotoxic tyrosine metabolites, resulting in severe liver injury. These mice
have been crossed with recombination activating gene 2 knockout (RAG2-/-) and IL-2 receptor γ-chain
knockout (IL-2Rγ-/-) mice, then designated FRG mice [124]. Both of these two types of humanized
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mice have been used to study other hepatotropic pathogens, such as HCV, HBV, HDV, and Plasmodium
falciparum [125–128].
Sayed et al. reported that when three uPA-SCID mice were inoculated with cell culture derived
HEV genotype 3 Kernow C1-P6 (1.7 × 106 IU/mouse), viral RNA could be detected in stool of two
out of the three infected mice, with titers reaching around 6.2 × 104 IU/mL [117]. Furthermore, when
filtered stool suspension from an HEV genotype 1 (Sar-55) infected chimpanzee was intrasplenically
inoculated into two mice, both tested positive for HEV RNA (stool and plasma) from week 1 post
inoculation. In fact, the magnitude of the infection with genotype 1 was much more robust compared
to genotype 3 [117]. Elsewhere, Van de Garde et al. showed that intravenous inoculation of fecal and
liver derived inocula (HEV genotype 3 positive) into uPA+/+Nod-SCID-IL2Rγ−/− mice resulted in
productive infection [118].
We used humanized FRG mice to compare different routes of inoculation. Intrasplenic inoculation
with a filtered patient stool suspension of HEV genotype 3 established infection in mice, with viral
RNA in feces and delayed viremia. Inoculation with plasma from the same patient also established
infection in one of two tested mice, however levels of fecal viral shedding were lower compared to
inoculation with stool. Additionally, mice were also subjected to a genotype 1 strain (Sar-55) and RNA
reached 104 IU/mL from week 2 post-infection [129]. Oral inoculation in both humanized uPA-SCID
and FRG mice did not result in a productive infection [117,129]. Humanized uPA-SCID mice have also
been used to determine the infectivity of cell culture-derived virus preparations [8].
Next to uPA-SCID, uPA+/+Nod-SCID-IL2Rγ−/−, and FRG mice, other mice strains have been
subjected to HEV, such as BALB/c mice and C57BL/6 mice. However, opposing results have been
published using these wild type animals. Huang et al. reported successful infection of Balb/c nude
mice with a swine feces-derived genotype 4 HEV. Infection was evidenced by HEV antigens and
RNA in liver, spleen, kidney, jejunum, ileum, and colon, elevated liver enzymes, and anti-HEV IgG
in sera [130]. Recently, the same group has also used regular Balb/c mice and infected them with a
full-length swine HEV cDNA clone of genotype 4, constructed via reverse genetics. HEV RNA was
detected in feces, serum, and tissues, such as liver, spleen, colon, and kidney [131].
Additionally, Sun et al. have succeeded in infecting Balb/c mice with a rabbit strain of HEV
genotype 3 via fecal-oral route. The infected mice showed inflammatory lesions in liver, comparable
with those observed in rabbits. HEV infection was evidenced with shedding of virus in feces, viremia,
and seroconversion [132]. In contrast, a study using different C57BL/6 mouse strains (wild-type,
IFNAR-/-, CD4-/-, and CD8-/-) and BALB/c nude mice failed to show infection of these animals when
inoculated intravenously and orally with a wild-boar derived HEV genotype 3 strain [101]. Accordingly,
Li et al. also failed to show infection of C57BL/6 mice when they were subjected to different HEV
inocula (domestic-pig-derived HEV of genotype 3, wild-boar-derived HEV of genotype 4, and stool
from a genotype 1 infected cynomolgus monkey). Viral RNA could not be detected in stool and serum
samples from the inoculated animals [133].
6.2. The Limitations of Mice as HEV Animal Model
The above-mentioned data shows that human-liver chimeric uPA and FRG mice are very promising
as small animal models for HEV research. However, the lack of a competent adaptive immune system
in these mice makes them inadequate to study the immune-mediated pathogenicity of HEV [51]. Thus,
the best option would be to utilize wild type immunocompetent mice, but these are still controversial
given the discrepancies between the above highlighted studies. One alternative approach could be
to humanize both the liver and immune system of the uPA-tg and FAH-KO models. Such dually
engrafted animals have been implemented and already proved, to some extent, useful to study the
human immune response upon hepatitis B infection [134,135].
Therefore, human liver chimeric mice seem to be the best option we currently have to study the
dynamics of HEV infection and to test the efficacy of novel therapeutic approaches. The uPA-SCID
model has already been validated for testing antivirals as a dose-dependent reduction of viral load
Viruses 2019, 11, 564 10 of 20
was observed after ribavirin treatment, the first-choice treatment in humans [117,119]. The model has
since been used to evaluate more experimental compounds, such as silvestrol [136].
7. Chicken Model
7.1. Avian HEV and Course of Infection in Chickens
Avian HEV was discovered in 2001 after isolation and characterization of the virus from the bile
of chickens who presented with hepatitis-splenomegaly syndrome (HSS) [137]. Phylogenetic analyses
revealed that the virus is genetically and antigenetically related and shares 60% sequence similarity
with human HEV strains [138]. Since then, other diseases observed in chickens, such as big liver and
spleen disease virus and hepatic rupture hemorrhage syndrome (HRHS), were shown to be caused by
avian HEV [139,140]. Moreover, certain subclinical infections in chickens could also be attributed to
avian HEV [141].
Chicken are the only known reservoir for avian HEV and the virus transmits easily between
flocks via fecal-oral route [142]. Experimentally, chicken have been inoculated with avian HEV via
intravenous or oronasal route. Upon infection, virus is shed in feces and viral RNA can be detected in
serum, bile, and liver samples. Moreover, liver lesions characterized by subcapsular hemorrhages and
enlarged lobe and periphlebitis. as well as lymphocytic phlebitis, can be observed in about 25% of
infected chickens [143].
7.2. Chicken as an Animal Model and Its Limitations
The discovery of avian HEV and its relation to human HEV allows for the use of chicken as a
homologous animal model to study HEV replication and pathogenesis. However, chickens are not
susceptible to human or swine HEV and the observed clinical signs of infected do not correspond to
the clinical signs in humans.
To gain insight into the morbidity and mortality associated with genotype 1 infections in pregnant
women, chickens have been used to study vertical transmission. Guo et al. reported that infectious
virus could be found in egg white from infected chickens. Unfortunately, no virus could be detected in
the samples from hatched chicks, meaning that vertical transmission could not be completed [144].
Chickens have shown to be useful for vaccine studies, as immunization of chicken with an avian
recombinant ORF2 capsid protein showed protective immunity against avian HEV infection, as none
of the immunized chickens had detectable viremia, fecal virus shedding, or observable hepatitis
lesions [145].
8. Other Small Animal Models
Alongside the described models, there are a few other animals that have proven to be useful for
HEV research. One of those is the ferret. A ferret strain of HEV was first described in the Netherlands
in 2010 and now appears to be widespread around the world [111,146,147]. Ferret HEV is distinct
from human HEV, shares the highest similarity with rat HEV, and is assigned to the Orthohepevirus
C species [111]. Therefore, the use of ferrets as an animal model to test antivirals or vaccines for
humans is less relevant [26]. Experimental infection of ferrets leads to either subclinical infection,
acute hepatitis, or persistent infection with detection of RNA in stool and sera, seroconversion, and
significant elevation of alanine transaminase (ALT) [148]. The development of persistent infection
was observed in 6 of 63 ferrets, and this is quite noteworthy as it developed naturally and not as a
consequence of an immunosuppressive drug regimen [148]. Ferret HEV could not be replicated in
Wistar rats, nude rats, or cynomolgus macaques [56].
Mongolian gerbils have also been shown to be susceptible to HEV. Gerbils could be experimentally
infected with a genotype 4 swine HEV and a genotype 1 human strain. Infection with the former led to
fecal viral shedding, elevation of liver transaminases, seroconversion, histopathological changes, and the
virus could be detected in liver as well as sporadically in the kidney, spleen, and small intestine [149,150].
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Infection with the human strain also led to fecal viral shedding and histopathological changes in liver,
spleen, and kidney [151]. Gerbils have been used to study extrahepatic manifestations associated
with HEV. It was reported that HEV RNA could be detected in the brain and spinal cord of genotype
4 infected animals, resulting in pathological changes in the brain and spinal cord. These observed
pathological changes include degeneration and necrosis of neurons and Pirkinje cells, infiltration
of inflammatory cells in ependymal epithelium and choroid plexus, and hemorrhages in choroid
plexus, dorsal median septum, and central canal of the spinal cord. These are in accordance with the
neurological manifestations observed in humans. As a consequence, gerbils prove useful for studying
neurological disorders associated with HEV infection [106,152]. Furthermore, Soomro et al. examined
the effect of HEV on testis tissue in genotype 4 infected animals. They showed that the structural and
molecular changes upon infection were able to disrupt the blood-testis barrier and induce germ cell
apoptosis [153]. The gerbil model was also used to evaluate the role of mast cells during infection,
which appear to increase upon disease progression in various liver disorders. It was demonstrated that
the amount of mast cells increased in the liver and small intestines upon infection, as well as higher
expression of tryptase and serotonin, which indicate activation of the cells [154].
9. Conclusions
HEV is a worldwide underdiagnosed pathogen and the study of the underlying molecular
mechanisms of HEV replication, pathogenesis, and more particularly, the host immune response,
observation of chronic infection in immunocompromised patients, and severe outcomes in pregnant
women have long been hampered due to an inefficient cell culture system and lack of convenient
animal models. However, together with increasing recognition of this pathogen, improvements of both
in vitro and in vivo models have emerged. The expanding host range of HEV has led to several new
experimental and naturally occurring animal models, offering opportunities for future HEV research
with strains from humans, pigs, wild boar, rabbits, and camels that are able to cause experimental
cross-species infection (Figure 1). Although the ideal animal model mimicking all aspects of viral
infection and disease progression in humans is yet to be identified, multiple of those aspects can be
studied in some of the aforementioned models.
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Figure 1. Successful experimental cross-species i ctions. A variety of human genotypes have been
shown to cross the species barrier and infect human liver chimeric mice, gerbils, pigs, macaques, and
chimpanzees. Genotype 3 and 4 isolated from pigs can cause infection in the non-human primate
models, whereas BALB/c nud mic , gerbils, and rabbits were only s sceptible to genotype 4 swine
HEV. Rabbit HEV can replicated in pigs, BALB/c nude mice, and cynomolgus macaques, and rabbits
themselves are prone to wild-boar derived genotype 3 HEV. Camel genotype 8 HEV and wild boar
derived genotype 5 can infect cynomolgus macaques.
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